EUVIMEDEUVIMED entdecken
Metaanalyse

Sodium‐glucose co‐transporter‐2 inhibitors and the risk of venous thromboembolism: A nationwide population‐based study and meta‐analysis

Natrium-Glukose-Kotransporter-2-Inhibitoren und das Risiko venöser Thromboembolien: landesweite populationsbasierte Studie und Metaanalyse

Hou-Ren Tsai, Yu-Jie Lin, Jih-I Yeh, Yu-Chi Huang, Peter Pin-Sung Liu, Carol Chiung-Hui Peng, Jin-Yi Hsu, Yuan-Chieh Lee, Ching-Hui Loh, Shu-Man Lin, Huei-Kai Huang iD

Diabetes/Metabolism Research and Reviews · 2024-02 · 40 (2)

DOI: 10.1002/dmrr.3739 ↗

Auf einen Blick

Bei Diabetes war SGLT-2i mit geringerem VTE-Risiko als DPP-4i verbunden. Gegenüber GLP-1RA zeigte sich kein Unterschied.

Fragestellung

Wie ist das VTE-Risiko unter SGLT-2i im Vergleich zu DPP-4i oder GLP-1RA bei Patient:innen mit Diabetes mellitus?

Methode

Retrospektive Kohortenstudie mit Daten aus Taiwans National Health Insurance Research Database; zusätzlich Metaanalyse publizierter Arbeiten vor dem 23. Mai 2023.

Ergebnisse

136.530 SGLT-2i-, 598.280 DPP-4i- und 5.760 GLP-1RA-Anwender:innen. VTE-Risiko: SGLT-2i vs. DPP-4i HR 0,70 (95 %-KI 0,59–0,84; p < 0,001), SGLT-2i vs. GLP-1RA HR 1,39 (95 %-KI 0,32–5,94; p = 0,66). Metaanalyse: HR 0,71 bzw. 0,91.

Schlussfolgerung der Autor:innen

Bei Patient:innen mit Diabetes war SGLT-2i mit einem geringeren VTE-Risiko als DPP-4i assoziiert, aber nicht im Vergleich zu GLP-1RA.

Kernaussagen

  • SGLT-2i vs. DPP-4i: HR 0,70 (95 %-KI 0,59–0,84)
  • SGLT-2i vs. GLP-1RA: kein signifikanter Unterschied
  • Metaanalyse bestätigte die retrospektiven Ergebnisse

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Metaanalyse in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 20.10.2023. Verfasst von Hou-Ren Tsai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Venous Thromboembolism, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Hualian Tzu Chi Hospital.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) have off‐target effects on haemoconcentration and anti‐inflammation. The impact of SGLT‐2i on the risk of venous thromboembolism (VTE) in patients with diabetes mellitus (DM) remains unclear. This study aimed to evaluate the risk of newly diagnosed VTE in patients with DM using SGLT‐2i in comparison to dipeptidyl peptidase‐4 inhibitors (DPP‐4i) or glucagon‐like peptide‐1 receptor agonists (GLP‐1RA). Materials and Methods In this nationwide retrospective cohort study, we used data from Taiwan's National Health Insurance Research Database. Patients with diabetes aged 20 years or older who received SGLT‐2i, DPP‐4i, or GLP‐1RA between 1 May 2016, and 31 December 2020, were included. The risks of VTE in SGLT‐2i users were compared with those of DPP‐4i and GLP‐1RA users. A Cox regression model with stabilised inverse probability of treatment weighting was used to calculate hazard ratio (HR) for VTE risk. Additionally, a meta‐analysis of relevant articles published before 23 May 2023, was conducted.

Results

Data from 136,530 SGLT‐2i, 598,280 DPP‐4i, and 5760 GLP‐1RA users were analysed. SGLT‐2i use was associated with a lower risk of VTE than DPP‐4i (HR, 0.70; 95% CI, 0.59–0.84; p < 0·001), but not with GLP‐1RA (HR, 1.39; 95% CI, 0.32–5.94; p = 0.66). Our meta‐analysis further supported these findings (SGLT‐2i vs. DPP‐4i: HR, 0.71; 95% CI, 0.62–0.82; p < 0·001; SGLT‐2i vs. GLP‐1RA: HR, 0.91; 95% CI, 0.73–1.15; p = 0.43), suggesting the robustness of our retrospective analysis.

Conclusions

In patients with DM, SGLT‐2i was associated with a lower risk of VTE compared to DPP‐4i, but not GLP‐1RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Venous ThromboembolismDipeptidyl-Peptidase IV InhibitorsSymportersHumansHypoglycemic AgentsRetrospective StudiesGlucoseSodiumGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

SGLT-2 inhibitorscohort studydiabetes mellitussodium-glucose cotransporter-2 inhibitorsvenous thromboembolism

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsDipeptidyl-Peptidase IV InhibitorsSymportersGlucoseSodiumGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Ophthalmology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
  • Health Information Center, Tzu Chi University, Hualien, Taiwan.
  • School of Medicine, Tzu Chi University, Hualien, Taiwan.
  • Department of Family Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
  • Center for Aging and Health, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
  • Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan.

ORCID-Profile: Huei-Kai Huang

Förderung

  • Hualian Tzu Chi Hospital

Zitieren

APA

Tsai, H. R., Lin, Y. J., Yeh, J. I., Huang, Y. C., Liu, P. P., Peng, C. C., Hsu, J. Y., Lee, Y. C., Loh, C. H., Lin, S. M., & Huang, H. K. (2024). Sodium‐glucose co‐transporter‐2 inhibitors and the risk of venous thromboembolism: A nationwide population‐based study and meta‐analysis. Diabetes/Metabolism Research and Reviews, 40(2). https://doi.org/10.1002/dmrr.3739

Vancouver

Tsai HR, Lin YJ, Yeh JI, Huang YC, Liu PP, Peng CC, et al. Sodium‐glucose co‐transporter‐2 inhibitors and the risk of venous thromboembolism: A nationwide population‐based study and meta‐analysis. Diabetes/Metabolism Research and Reviews. 2024;40(2). doi:10.1002/dmrr.3739

BibTeX
@article{Tsai2024,
  author = {Tsai, Hou-Ren and Lin, Yu-Jie and Yeh, Jih-I and Huang, Yu-Chi and Liu, Peter Pin-Sung and Peng, Carol Chiung-Hui and Hsu, Jin-Yi and Lee, Yuan-Chieh and Loh, Ching-Hui and Lin, Shu-Man and Huang, Huei-Kai},
  title = {Sodium‐glucose co‐transporter‐2 inhibitors and the risk of venous thromboembolism: A nationwide population‐based study and meta‐analysis},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2024},
  volume = {40},
  number = {2},
  doi = {10.1002/dmrr.3739}
}
Kostenlos starten →